Shots:

• Numab to receive ~$279.13M in research funding, up front and milestone along with royalties on future sales. Under the terms of the license agreement, Ono gets the intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target
• The collaboration will combine Numab’s multispecific antibody platform and Ono’s deep immuno-oncology expertise to advance the immuno-oncology pipeline for cancer patients
• In Mar 2020, Numab has expanded its collaboration with Ono to discover and develop a multispecific antibody drug candidate for the treatment of multiple cancers

Ref: Businesswire | Image: Businesswire